Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
30 Ottobre 2024 - 9:02PM
Business Wire
Adds Andrea Natale, M.D. as a medical advisor, joining existing
advisors Vivek Reddy, M.D. and Jacob Koruth, M.D.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its
novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™)
technology, today announced the appointment of David Kenigsberg,
M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale,
M.D. will become a medical advisor for the company, joining
existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who
altogether will continue to support the development and clinical
efforts for the Pulse Biosciences nano-PFA 360 Cardiac
Catheter.
“I am inspired by the potential of nano-PFA and the unique
catheter design of the 360 catheter that is already demonstrating
the ability to isolate pulmonary veins with ease and speed,” said
Dr. David Kenigsberg, Chief Medical Officer of Electrophysiology of
Pulse Biosciences. “I was impressed when I saw the 360 catheter in
use and am excited to work with Pulse to deliver robust clinical
data with the 360, which I believe will substantially advance the
treatment of atrial fibrillation. I look forward to supporting this
team through its next phase of clinical development.”
Dr. Kenigsberg is a practicing cardiac electrophysiologist with
a passion for treating atrial fibrillation over his career. He is
the founder of Florida Heart Rhythm Specialists and Ft. Lauderdale
Heart & Rhythm Surgical Center. He has been the Medical
Director of the Electrophysiology Lab at HCA Westside Medical
Center in Plantation, Florida, since 2007. He has published
numerous scholarly articles in peer-reviewed medical journals. He
has advised in the development and has been the primary
investigator/co-investigator in a myriad of clinical trials
involving ablation tools. Dr. Kenigsberg is a fellow of the
American College of Cardiology and the Heart Rhythm Society. He is
the President of the Florida Chapter of the American College of
Cardiology and sits on the American College of Cardiology Board of
Governors.
“This is an exciting time in electrophysiology as pulsed field
ablation technologies are becoming widely adopted and advancing the
standard of care. I am excited to support the Pulse team in the
clinical efforts for the 360 catheter,” added Dr. Andrea
Natale.
Dr. Andrea Natale is the Executive Medical Director of the Texas
Cardiac Arrhythmia Institute at St. David’s Medical Center in
Austin, Texas, and the National Medical Director of Cardiac
Electrophysiology for HCA Healthcare. A dedicated researcher and
pioneer, Dr. Andrea Natale focuses on innovative advances in the
treatment of atrial fibrillation. He has been, and continues to be,
involved in many first-in-human trials to test investigational
devices, recently performing the first pre-clinical and clinical
studies to develop and perfect ablation catheters utilizing a
novel, groundbreaking ablation energy source known as irreversible
electroporation.
Burke T. Barrett, President and Chief Executive Officer of Pulse
Biosciences concluded, “We are significantly strengthening our team
with the addition of these renowned physicians who will contribute
to generating high quality clinical data that demonstrates the
clinical performance profile of the 360 catheter. I want to thank
Drs. Reddy and Koruth for their significant contributions in the
pre-clinical and clinical evaluations of the 360 catheter to
date.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary CellFX®
nsPFA™ technology delivers nanosecond pulses of electrical energy
to non-thermally clear cells while sparing adjacent noncellular
tissue. The Company is actively pursuing the development of its
CellFX nsPFA technology for use in the treatment of atrial
fibrillation and in a select few other markets where it could have
a profound positive impact on healthcare for both patients and
providers. Pulse Biosciences is now headquartered in Miami, Florida
and maintains its office in Hayward, California.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA,
CellFX nsPFA and the stylized logos are among the trademarks and/or
registered trademarks of Pulse Biosciences, Inc. in the United
States and other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030976724/en/
Investors: Pulse Biosciences, Inc. Burke T. Barrett,
President and CEO IR@pulsebiosciences.com
Or
Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Grafico Azioni Pulse Biosciences (NASDAQ:PLSE)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Pulse Biosciences (NASDAQ:PLSE)
Storico
Da Gen 2024 a Gen 2025
